Library of Scientific Studies Funded and Published by others and Hepatitis C articles from other sources..

Sen. John Kerry & Rep. Michael Honda Introduce Hepatitis C Legislation

A silent killer is loose in America. It contributes to the death of 15,000 Americans a year and threatens the health of 5.3 million more. It is more common than HIV/AIDS. It is the leading cause of liver cancer - a cancer that is on the rise and continues to be a fatal and costly disease. Yet it remains unrecognized as a serious threat to public health.

Having a Tattoo Associated With Tripled Risk of Dangerous Disease

The global fad for tattoos, particularly among young people, is growing -- and along with it the risk of acquiring hepatitis C, according to a multinational study.A systematic review of 124 published studies from 30 countries found
that people with tattoos were almost three times as likely to have
hepatitis C as those without tattoos, according to Dr. Jane Buxton of
the British Columbia Centre for Disease Control in Vancouver and

New Use for Old Drugs in Treating Hepatitis C?

Research led by the University of Leeds has found drugs such as anti-diabetic drug Metformin and AICAR, used to combat obesity, can prevent the hepatitis C virus from replicating in the body. Hepatitis C virus affects
an estimated three per cent of the world’s population and there are four million carriers of the virus in Europe alone. The virus affects the liver and recovery rates are low: only around 40 % of hepatitis C sufferers will fully
recover, with others developing cirrhosis and in many cases, liver cancer.

OraSure delays filing for oral version of hep C test

Aug 4 (Reuters) - OraSure Technologies Inc (OSUR.O) said it has delayed the filing of a new version of its recently approved hepatitis C virus test after the U.S. health regulator commented on its lower sensitivity.

The primary comments from regulators were related to the lower sensitivity of the oral fluid and fingerstick whole blood versions of the test, OraQuick HCV, compared to the venous whole blood version, which is already on the market.

Depression overlooked in patients with hepatitis C; compromising HCV therapy

Lower patient productivity and higher healthcare benefit costs add to burden of HCV infection

Researchers from Denmark, Sweden, Norway and Finland (the NORDynamIC project group) have observed that depressive symptoms in patients with hepatitis C virus (HCV) infection are commonly overlooked in routine clinical interviews, and that treatment-induced depression compromises the outcome of HCV therapy. A second U.S.

FTC Imposes a New Standard for Competent and Reliable Scientific Evidence

This was forwarded to us regarding another companies dealings with FTC / FDA regulations on free speech.

Client Alert

A few months ago, we notified you that the Federal Trade Commission (“FTC” or “Commission”) intended to change its standard for “competent and reliable scientific evidence” as it applies to claims for over-the-counter (“OTC”) drugs, dietary supplements and functional foods, starting by imposing the new standard on individual companies through consent decrees. Now, as predicted, the FTC has introduced that new standard into consent decrees with Iovate Health Sciences, Inc. (“Iovate”) and Nestle HealthCare Nutrition, Inc. (“Nestle”).

Specifically, yesterday’s FTC consent decree with Iovate Health Sciences imposed a provision under which Iovate is barred from representing that its products cause weight loss or rapid weight loss unless the claims are truthful and backed by “competent and reliable scientific evidence” in the form of:

1.    At least two adequate and well-controlled human clinical studies,
2.    of the product at issue or an essentially equivalent product
3.    conducted by different experts independently of each other,
4.    that conform to acceptable designs and protocols and whose results, when
considered in light of the entire body of relevant and reliable scientific evidence, are sufficient to substantiate the claim.

The Chemo Concession Persists - Part II

Part 1 Here

"In sum, far from limiting access," the changes under the law "actually increased the likelihood that lung cancer patients received chemotherapy," said Dr. Mireille Jacobson of the RAND Corporation, who was first author on the study. (Disclosure: I serve as a reviewer of scientific studies for RAND.)

The authors chose to focus on lung cancer because of the various treatment options, some of which are considerably more expensive than others. They found that doctors frequently switched drugs to choose the more expensive options. There was, for instance, an increased use of docetaxel (Taxotere), a drug for which oncologist get reimbursed about $2,500 per patient per month.

Syndicate content